Company: Cypress Bioscience
Starting stock price: $7.64
Ending stock price: $11.03
Percent Change: 44.37%
Details: Last year Cypress Bioscience marked several big milestones. On May 22, the company wrapped up a second Phase III trial of its drug candidate milnacipran, a dual-reuptake inhibitor that acts on norepinephrine and serotonin. The company is trying to commercialize it for use against fibromyalgia. Then, May 31, Cypress launched a public offering of 4.7 million shares.
Cypress then presented the results to the American College of Rheumatology in November: Milnacipran delivered â€œstatistically significant and clinically meaningful improvements in both pain and other core symptoms associated with fibromyalgia,â€ the company announced. By yearâ€™s end, the company and its development partner Forrest Laboratories submitted a new drug application with the FDA. The compound already is approved for use in more than 50 countries.